Biocom’s Terri Somers dropped the newest issue of Deals and Data just before the holiday weekend.

She hits on several issues that we’ve been keeping an eye on. Among them are Sequenom’s troubles, which have now drawn the attention of the Securities and Exchange Commission, Arena’s struggle to get back in Wall Street’s good graces and a tidbit on Metabasis, a company that I wrote about Sunday.

DAVID WASHBURN

Leave a comment

We expect all commenters to be constructive and civil. We reserve the right to delete comments without explanation. You are welcome to flag comments to us. You are welcome to submit an opinion piece for our editors to review.

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.